Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sleep and Cognitive Function in Multiple Sclerosis.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sex hormones and multiple sclerosis: another informative failure.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Development of a Bilingual MS-Specific Health Classification System: The Preference-Based Multiple Sclerosis Index.
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.
Optical Coherence Tomography in Multiple Sclerosis.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-dose Gadolinium
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Association between beta-interferon exposure and hospital events in multiple sclerosis.
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis.

Pages